Effect of dexamethasone in patients with ARDS and COVID-19 (REMED trial)—study protocol for a prospective, multi-centre, open-label, parallel-group, randomized controlled trial
Authors:
- Jan MaláskaJMJan Maláska
- Jan StašekJSJan Stašek
- František DuškaFDFrantišek Duška
- Martin BalíkMBMartin Balík
- Jan MácaJMJan Máca
- Jan HrudaJHJan Hruda
- Tomáš VymazalTVTomáš Vymazal
- Olga KlementováOKOlga Klementová
- Jan ZatloukalJZJan Zatloukal
- Tomáš GabrhelíkTGTomáš Gabrhelík
- Pavel NovotnýPNPavel Novotný
- Regina DemlováRDRegina Demlová
Open Access
- 15 January 2022
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-15
Abstract
Background: Since December 2019, SARS-CoV-2 virus has infected millions of people worldwide. In patients with COVID-19 pneumonia in need of oxygen therapy or mechanical ventilation, dexamethasone 6 mg per day is currently recommended. However, the dose of 6 mg of dexamethasone is currently being reappraised and may miss important therapeutic potential or may prevent potential deleterious effects of higher doses of corticosteroids. Methods: REMED is a prospective, open-label, randomised controlled trial testing the superiority of dexamethasone 20 mg (dexamethasone 20 mg on days 1–5, followed by dexamethasone 10 mg on days 6–10) vs 6 mg administered once daily intravenously for 10 days in adult patients with moderate or severe ARDS due to confirmed COVID-19. Three hundred participants will be enrolled and followed up for 360 days after randomization. Patients will be randomised in a 1:1 ratio into one of the two treatment arms. The following stratification factors will be applied: age, Charlson Comorbidity Index, CRP levels and trial centre. The primary endpoint is the number of ventilator-free days (VFDs) at 28 days after randomisation. The secondary endpoints are mortality from any cause at 60 days after randomisation; dynamics of the inflammatory marker, change in WHO Clinical Progression Scale at day 14; and adverse events related to corticosteroids and independence at 90 days after randomisation assessed by the Barthel Index. The long-term outcomes of this study are to assess long-term consequences on mortality and quality of life at 180 and 360 days. The study will be conducted in the intensive care units (ICUs) of ten university hospitals in the Czech Republic. Discussion: We aim to compare two different doses of dexamethasone in patients with moderate to severe ARDS undergoing mechanical ventilation regarding efficacy and safety. Trial registration: EudraCT No. 2020-005887-70. ClinicalTrials.gov NCT04663555. Registered on December 11, 2020Keywords
All Related Versions
Funding Information
- Ministerstvo Zdravotnictví Ceské Republiky (FNBr, 65269705)
- Donatio Intensivistam (No 0907206)
- CZECRIN (LM2018128)
- ERDF (CZ.02.1.01/0.0/0.0/16_013/0001826)
This publication has 17 references indexed in Scilit:
- Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19JAMA, 2020
- Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19JAMA, 2020
- COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort studyThe Lancet Rheumatology, 2020
- A minimal common outcome measure set for COVID-19 clinical researchThe Lancet Infectious Diseases, 2020
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, ChinaJAMA Internal Medicine, 2020
- Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trialThe Lancet Respiratory Medicine, 2020
- Contemporary strategies to improve clinical trial design for critical care research: insights from the First Critical Care Clinical Trialists WorkshopIntensive Care Medicine, 2020
- International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumoniaEuropean Respiratory Journal, 2017
- SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trialsBMJ, 2013
- Methylprednisolone Infusion in Early Severe ARDSChest, 2007